SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 8.4% – Should You Sell?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) fell 8.4% during trading on Monday . The company traded as low as $14.17 and last traded at $14.1580. 2,469,527 shares traded hands during trading, a decline of 70% from the average daily volume of 8,216,982 shares. The stock had previously closed at $15.46.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Friday, July 17th. Alliance Global Partners restated a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, August 12th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, SELLAS Life Sciences Group currently has an average rating of “Hold” and a consensus price target of $10.00.

SELLAS Life Sciences Group Trading Down 1.6%

The stock has a market capitalization of $2.85 billion, a price-to-earnings ratio of -67.09 and a beta of 2.48. The business has a 50 day simple moving average of $12.11 and a 200-day simple moving average of $7.90.

SELLAS Life Sciences Group (NASDAQ:SLS) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01).

Institutional Trading of SELLAS Life Sciences Group

Several institutional investors have recently made changes to their positions in the stock. California State Teachers Retirement System increased its stake in SELLAS Life Sciences Group by 22.4% during the first quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock worth $39,000 after acquiring an additional 1,709 shares during the last quarter. Nykredit A S acquired a new position in shares of SELLAS Life Sciences Group in the 2nd quarter valued at about $27,000. Grange Capital LLC lifted its stake in shares of SELLAS Life Sciences Group by 18.5% in the 4th quarter. Grange Capital LLC now owns 16,001 shares of the company’s stock valued at $60,000 after purchasing an additional 2,500 shares in the last quarter. Invesco Ltd. grew its holdings in shares of SELLAS Life Sciences Group by 6.2% during the 4th quarter. Invesco Ltd. now owns 53,293 shares of the company’s stock worth $201,000 after purchasing an additional 3,114 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of SELLAS Life Sciences Group by 13.6% during the 4th quarter. The Manufacturers Life Insurance Company now owns 38,018 shares of the company’s stock worth $143,000 after purchasing an additional 4,564 shares during the period. 17.38% of the stock is owned by hedge funds and other institutional investors.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.